1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

Primary Author / Presenter(s)

Talha Munir, MBBS, MRCP, FRCPath, PhD

Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom

Co-Author(s)

SG

Sean Girvan, MSc

University of Leeds
Leeds, England, United Kingdom
DC

David Cairns, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AB

Adrian Bloor, MA, MB, Bchir, PhD, FRCP, FRCPath

Christie Hospital NHS Trust
Manchester, England, United Kingdom
DA

David Allsup, MD, Phd

Department Hematology, Hull University Teaching Hospitals NHS Trust
Hull, England, United Kingdom
AV

Abraham Varghese, MB BS, PhD

Clinical Haematology, Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
SG

Satyen H. Gohil, PhD

University College London Hospitals NHS Foundation Trust
London, England, United Kingdom
SP

Shankara Paneesha, MBChB

University Hospitals Birmingham
Birmingham, England, United Kingdom
AP

Andrew Pettitt

Professor in Haematology
University of Liverpool
Liverpool, England, United Kingdom
TE

Toby A. A. Eyre, MRCP, FRCPath, MD

Consultant Haematologist
Churchill Hospital, Oxford University
Oxford, England, United Kingdom
CF

Christopher P. Fox

Consultant Haematology
Organization
Nottingham, England, United Kingdom
FF

Francesco Forconi, MD

University Hospital Southampton NHS Trust
Southampton, England, United Kingdom
CB

Constantine Balotis, MD

University Hospitals of Leicester NHS Trust
Leicester, England, United Kingdom
NP

Nicholas Pemberton, FRCPath

Worcestershire Acute Hospitals NHS Trust
Worcester, England, United Kingdom
OS

Oonagh Sheehy, FRCPath

Belfast City Hospital
Belfast, Northern Ireland, United Kingdom
John Gribben

Professor
Barts Cancer Institute
Barts Cancer Institute
London, England, United Kingdom
NE

Nagah Elmusharaf, FRCPath

Consultant Haematologist
University Hospital of Wales
Cardiff, Wales, United Kingdom
SG

Simona Gatto, PhD

University Hospital of Wales
Cardiff, Wales, United Kingdom
GP

Gavin Preston, PhD

Consultant Haematologist
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom
Anna Schuh, MD, PhD

Professor
Churchill Hospital, Oxford University
Oxford, England, United Kingdom
RW

Renata Walewska, MD

Consultant Haematologist
University Hospitals Dorset
Bournemouth, England, United Kingdom
LD

Lelia Duley

CLL Support Association
Nottingham, England, United Kingdom
NW

Nichola Webster

University of Leeds
Leeds, England, United Kingdom
SD

Surita Dalal, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds
University of Leeds
Leeds, England, United Kingdom
AR

Andy Rawstron, PhD

Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
DH

Dena Howard, PhD

Roche
Leeds, England, United Kingdom
AH

Anna Hockaday

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds
Leeds, England, United Kingdom
SJ

Sharon Jackson, PhD

University of Leeds
Leeds, England, United Kingdom
NG

Natasha Greatorex, BSc

University of Leeds
Leeds, England, United Kingdom
SB

Sue Bell, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
DS

David Stones, MSc

University of Leeds
Leeds, England, United Kingdom
JB

Julia Brown, MSc

University of Leeds
Leeds, England, United Kingdom
Piers Patten, BSc, MBChB, PhD

Clinical Senior Lecturer, Consultant Haematologist
King's College London
London, England, United Kingdom
Peter Hillmen, MD, PhD

Professor of Experimental Haematology
University of Leeds
St. James University Hospital
Leeds, England, United Kingdom